Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company advancing targeted therapies for cardiometabolic disease.

Backed by experienced leadership and world-class investors, we are pushing a bold vision to improve outcomes for patients who remain underserved by today’s standard-of-care.

We are focused on delivering a new treatment option for patients with inadequately controlled type 2 diabetes in whom elevated cortisol is a common driver of disease progression and treatment resistance. CAPTAIN-T2D is a Phase 2b clinical trial evaluating clofutriben, a novel HSD-1 inhibitor, for difficult-to-control type 2 diabetes.